Cargando…
l-Ornithine l-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses
This manuscript represents an appraisal of the evidence in support of l-ornithine-l-aspartate (LOLA) for the management and treatment of hepatic encephalopathy (HE) in cirrhosis. Meta-analyses of randomized controlled trials (RCTs) conducted over the last two decades generally reveal evidence of ben...
Autores principales: | Butterworth, Roger F., McPhail, Mark J. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416237/ https://www.ncbi.nlm.nih.gov/pubmed/30706425 http://dx.doi.org/10.1007/s40265-018-1024-1 |
Ejemplares similares
-
Pharmacokinetic and Pharmacodynamic Properties of l-Ornithine l-Aspartate (LOLA) in Hepatic Encephalopathy
por: Kircheis, Gerald, et al.
Publicado: (2019) -
Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis
por: Butterworth, Roger F.
Publicado: (2019) -
l-Ornithine l-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease
por: Canbay, Ali, et al.
Publicado: (2019) -
Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs
por: Ahn, Jin-Ok, et al.
Publicado: (2016) -
Effect of Rifaximin, Probiotics, and l-Ornithine l-Aspartate on Minimal Hepatic Encephalopathy: A Randomized Controlled Trial
por: Sharma, Kapil, et al.
Publicado: (2014)